Establishing a core outcome set for creatine transporter deficiency and guanidinoacetate methyltransferase deficiency

By afschroeder • August 8, 2025

Nasseri Moghaddam Z, Reinhardt EK, Thurm A, Potter BK, Smith M, Graham C, Tiller BH, Baker SA, Bilder DA, Bogar R, Britz J, Cafferty R, Coller DP, DeGrauw TJ, Hall V, Lipshutz GS, Longo N, Mercimek-Andrews S, Miller JS, Pasquali M, Salomons GS, Schulze A, Wheaton CP, Williams KF, Young SP, Li J, Balog S, Selucky T, Stöckler-Ipsiroglu S, Wallis H. Establishing a core outcome set for creatine transporter deficiency and guanidinoacetate methyltransferase deficiency. Orphanet J Rare Dis. 2025 Aug 7;20(1):408. doi: 10.1186/s13023-025-03900-3. PMID: 40775643.

Tags: Core outcome set (COS), Creatine transporter deficiency, Endocrinology, Guanidinoacetate methyltransferase deficiency, Patient focused drug development. Patient-centered research, Publications, rare disease

Stabilizing and strengthening the U.S. physician-scientist faculty workforce in academic medicine: a proposed institutional framework

Williams CS, Allen M, Cooper Byas P, Hawley JB, Muglia LJ, Abel ED, Bastarache JA, Calfee CS, Carethers JM, Cornfield DN, Eickelberg O, Gallagher EJ,[...]

The effectiveness of care coordination on medication adherence among high-need, high-cost commercially insured beneficiaries: A randomized controlled trial

Saju R, Harwood JM, Tseng CH, Moin T, Mangione C, Duru OK, Takada S, Onufrak S. The effectiveness of care coordination on medication adherence among[...]

Systems Genetics Reveals ITIH5 as a Key Mediator of Adipocyte-Endothelial Crosstalk

Zhou M, Velez LM, Kwan D, Moses L, Johnson CD, Nguyen CM, Mott L, Gamie F, Fouladi M, Bae H, Verlande A, Arneson D, Petrus[...]